{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:56:32Z","timestamp":1784073392486,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T00:00:00Z","timestamp":1486944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T00:00:00Z","timestamp":1486944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The pathophysiological implications of plasminogen activator inhibitor-1 (PAI-1) in HCV infection remain obscure. This prospective study evaluated 669 HCV patients, of whom 536 had completed a course of anti-HCV therapy and had pre-, peri- and post-therapy measurements of various profiles, including PAI-1 levels. Multivariate analysis demonstrated, before anti-HCV-therapy, platelet count and PAI-1-rs1799889 genotype were associated with PAI-1 levels. Among patients with a sustained virological response (SVR, n\u2009=\u2009445), platelet count was associated with PAI-1 level at 24 weeks post-therapy. GEE analysis showed that PAI-1-rs-1799889 and interferon-\u03bb3-rs12979860 genotypes affected PAI-1 levels early and late in therapy, respectively. At 24 weeks post-therapy, higher lipid, brain natriuretic peptide, homocysteine and PAI-1 levels and PAI-1 activity were noted only in SVR patients compared with pre-therapy levels. Within 24 weeks post-therapy, 2.2% of the SVR (mean age: 57.8\u2009yr; 8 smoking males; the 2 females had pre-therapy hypercholesteremia or cardiovascular family history of disease) and 0% of the non-SVR patients experienced a new cardiovascular event. Platelet counts consistently correlated with PAI-1 levels regardless of HCV infection. PAI-1-rs-1799889 and interferon-\u03bb3-rs12979860 genotypes mainly affected PAI-1 levels longitudinally. Within 24 weeks post-anti-HCV therapy, the SVR patients showed increasing PAI-1 levels with accelerating cardiovascular risk, especially the vulnerable cases.<\/jats:p>","DOI":"10.1038\/srep42503","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T10:18:20Z","timestamp":1486981100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance"],"prefix":"10.1038","volume":"7","author":[{"given":"Ming-Ling","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Heng","family":"Pao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Chih","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Tang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,13]]},"reference":[{"key":"BFsrep42503_CR1","doi-asserted-by":"publisher","first-page":"30799","DOI":"10.1038\/srep30799","volume":"6","author":"ML Chang","year":"2016","unstructured":"Chang, M. L. et al. Resistin reinforces interferon \u03bb-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms. Sci. Rep. 6, 30799 (2016).","journal-title":"Sci. Rep"},{"key":"BFsrep42503_CR2","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3748\/wjg.v22.i4.1461","volume":"22","author":"ML Chang","year":"2016","unstructured":"Chang, M. L. Metabolic alterations and hepatitis C: From bench to bedside. World J. Gastroenterol. 22, 1461\u20131476 (2016).","journal-title":"World J. Gastroenterol."},{"key":"BFsrep42503_CR3","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.3748\/wjg.v20.i11.2825","volume":"20","author":"U Vespasiani-Gentilucci","year":"2014","unstructured":"Vespasiani-Gentilucci, U., Gallo, P., De Vincentis, A., Galati, G. & Picardi, A. Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J. Gastroenterol. 20, 2825\u20132838 (2014).","journal-title":"World J. Gastroenterol."},{"key":"BFsrep42503_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/jgh.12705","volume":"30","author":"ML Chang","year":"2015","unstructured":"Chang, M. L. et al. Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders. J. Gastroenterol. Hepatol. 30, 329\u2013336 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFsrep42503_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1055\/s-0035-1550437","volume":"41","author":"FW Leebeek","year":"2015","unstructured":"Leebeek, F. W. & Rijken, D. C. The fibrinolytic status in liver diseases. Semin. Thromb. Hemost. 41, 474\u2013480 (2015).","journal-title":"Semin. Thromb. Hemost."},{"key":"BFsrep42503_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.coph.2004.10.003","volume":"5","author":"M Nieuwdorp","year":"2005","unstructured":"Nieuwdorp, M., Stroes, E. S., Meijers, J. C. & B\u00fcller, H. Hypercoagulability in the metabolic syndrome. Curr. Opin. Pharmacol. 5, 155\u2013159 (2005).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFsrep42503_CR7","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.surg.2015.04.053","volume":"158","author":"H Chen","year":"2015","unstructured":"Chen, H. et al. Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis. Surgery 158, 1704\u20131713 (2015).","journal-title":"Surgery"},{"key":"BFsrep42503_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/MOL.0b013e32814e6d29","volume":"18","author":"MC Alessi","year":"2007","unstructured":"Alessi, M. C., Poggi, M. & Juhan-Vague, I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr. Opin. Lipidol. 18, 240\u2013245 (2007).","journal-title":"Curr. Opin. Lipidol."},{"key":"BFsrep42503_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1160\/TH08-07-0490","volume":"100","author":"EY Dimova","year":"2008","unstructured":"Dimova, E. Y. & Kietzmann, T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: Lessons from the liver. Thromb. Haemost. 100, 992\u20131006 (2008).","journal-title":"Thromb. Haemost."},{"key":"BFsrep42503_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1055\/s-0034-1384635","volume":"40","author":"K Yamamoto","year":"2014","unstructured":"Yamamoto, K., Takeshita, K. & Saito, H. Plasminogen activator inhibitor-1 in aging. Semin. Thromb. Hemost. 40, 652\u2013659 (2014).","journal-title":"Semin. Thromb. Hemost."},{"key":"BFsrep42503_CR11","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1182\/blood-2012-06-436188","volume":"120","author":"J Huang","year":"2012","unstructured":"Huang, J. et al. Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood 120, 4873\u20134881 (2012).","journal-title":"Blood"},{"key":"BFsrep42503_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.thromres.2013.12.032","volume":"133","author":"E Incalcaterra","year":"2014","unstructured":"Incalcaterra, E. et al. Residual vein thrombosis and onset of post-thrombotic syndrome: Influence of the 4G\/5G polymorphism of plasminogen activator inhibitor-1 gene. Thromb. Res. 133, 371\u2013374 (2014).","journal-title":"Thromb. Res."},{"key":"BFsrep42503_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.gene.2013.10.035","volume":"534","author":"JN Hellwege","year":"2014","unstructured":"Hellwege, J. N. et al. Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics. Gene 534, 33\u201339 (2014).","journal-title":"Gene"},{"key":"BFsrep42503_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.thromres.2007.09.005","volume":"122","author":"AE Tsantes","year":"2008","unstructured":"Tsantes, A. E. et al. The effect of the plasminogen activator inhibitor-1 4G\/5G polymorphism on the thrombotic risk. Thromb. Res. 122, 736\u2013742 (2008).","journal-title":"Thromb. Res."},{"key":"BFsrep42503_CR15","doi-asserted-by":"publisher","first-page":"e104783","DOI":"10.1371\/journal.pone.0104783","volume":"9","author":"ML Chang","year":"2014","unstructured":"Chang, M. L. et al. Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance. PLOS ONE 9, e104783 (2014).","journal-title":"PLOS ONE"},{"key":"BFsrep42503_CR16","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.jacc.2010.05.049","volume":"56","author":"JG Smith","year":"2010","unstructured":"Smith, J. G. et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J. Am. Coll. Cardiol. 56, 1712\u20131719 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFsrep42503_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jhep.2007.07.026","volume":"48","author":"H Poustchi","year":"2008","unstructured":"Poustchi, H. et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J. Hepatol. 48, 28\u201334 (2008).","journal-title":"J. Hepatol."},{"key":"BFsrep42503_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jhep.2008.12.017","volume":"50","author":"CY Dai","year":"2009","unstructured":"Dai, C. Y. et al. Insulin resistance predicts response to peginterferon-alpha\/ribavirin combination therapy in chronic hepatitis C patients. J. Hepatol. 50, 712\u2013718 (2009).","journal-title":"J. Hepatol."},{"key":"BFsrep42503_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ijcard.2012.03.047","volume":"167","author":"RM Gu\u00e9ant Rodriguez","year":"2013","unstructured":"Gu\u00e9ant Rodriguez, R. M. et al. Homocysteine predicts increased NT-pro-BNP through impaired fatty acid oxidation. Int. J. Cardiol. 167, 768\u2013775 (2013).","journal-title":"Int. J. Cardiol."},{"key":"BFsrep42503_CR20","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.2337\/dc14-0669","volume":"37","author":"G Gruden","year":"2014","unstructured":"Gruden, G., Landi, A. & Bruno, G. Natriuretic peptides, heart, and adipose tissue: New findings and future developments for diabetes research. Diabetes Care 37, 2899\u20132908 (2014).","journal-title":"Diabetes Care"},{"key":"BFsrep42503_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.metabol.2013.11.017","volume":"63","author":"OA Sanchez","year":"2014","unstructured":"Sanchez, O. A. et al. The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: The multi-ethnic study of atherosclerosis. Metabolism 63, 475\u2013483 (2014).","journal-title":"Metabolism"},{"key":"BFsrep42503_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1021\/pr0499592","volume":"3","author":"H Lu","year":"2004","unstructured":"Lu, H., Li, W., Noble, W. S., Payan, D. & Anderson, D. C. Riboproteomics of the hepatitis C virus internal ribosomal entry site. J. Proteome Res. 3, 949\u2013957 (2004).","journal-title":"J. Proteome Res."},{"key":"BFsrep42503_CR23","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1111\/j.1365-2893.2011.01516.x","volume":"19","author":"D Miki","year":"2012","unstructured":"Miki, D. et al. Serum PAI-1 is a novel predictor for response to pegylated interferon-\u03b1-2b plus ribavirin therapy in chronic hepatitis C virus infection. J. Viral Hepat. 19, e126\u2013e133 (2012).","journal-title":"J. Viral Hepat"},{"key":"BFsrep42503_CR24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jhep.2016.01.009","volume":"64","author":"P Udompap","year":"2016","unstructured":"Udompap, P., Mannalithara, A., Heo, N. Y., Kim, D. & Kim, W. R. Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. J. Hepatol. 64, 1027\u20131032 (2016).","journal-title":"J. Hepatol."},{"key":"BFsrep42503_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.pharep.2015.05.022","volume":"67","author":"K Kramkowski","year":"2015","unstructured":"Kramkowski, K., Leszczynska, A. & Buczko, W. Pharmacological modulation of fibrinolytic response - In vivo and in vitro studies. Pharmacol. Rep. 67, 695\u2013703 (2015).","journal-title":"Pharmacol. Rep."},{"key":"BFsrep42503_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000073579","volume":"32","author":"I Juhan-Vague","year":"2002","unstructured":"Juhan-Vague, I., Morange, P. E. & Alessi, M. C. The insulin resistance syndrome: Implications for thrombosis and cardiovascular disease. Pathophysiol. Haemost. Thromb. 32, 269\u2013273 (2002).","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"BFsrep42503_CR27","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1161\/01.CIR.98.21.2241","volume":"98","author":"AM Th\u00f6gersen","year":"1998","unstructured":"Th\u00f6gersen, A. M. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98, 2241\u20132247 (1998).","journal-title":"Circulation"},{"key":"BFsrep42503_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0140-6736(87)93050-9","volume":"2","author":"A Hamsten","year":"1987","unstructured":"Hamsten, A. et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2, 3\u20139 (1987).","journal-title":"Lancet"},{"key":"BFsrep42503_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1055\/s-0038-1646415","volume":"66","author":"WL Chandler","year":"1991","unstructured":"Chandler, W. L. A kinetic model of the circulatory regulation of tissue plasminogen activator. Thromb. Haemost. 66, 321\u2013328 (1991).","journal-title":"Thromb. Haemost."},{"key":"BFsrep42503_CR30","doi-asserted-by":"crossref","unstructured":"Petta, S. et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: A meta-analysis of observational studies. Gastroenterology 150, 145\u2013155.e4 quiz e15 (2016).","DOI":"10.1053\/j.gastro.2015.09.007"},{"key":"BFsrep42503_CR31","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jama.290.7.898","volume":"290","author":"UN Khot","year":"2003","unstructured":"Khot, U. N. et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290, 898\u2013904 (2003).","journal-title":"JAMA"},{"key":"BFsrep42503_CR32","doi-asserted-by":"publisher","first-page":"e3546","DOI":"10.1097\/MD.0000000000003546","volume":"95","author":"JH Hu","year":"2016","unstructured":"Hu, J. H. et al. Sexual dimorphic metabolic alterations in hepatitis C virus-infected patients: a community-based study in a hepatitis B\/hepatitis C Virus hyperendemic area. Med. Baltimore 95, e3546 (2016).","journal-title":"Med. Baltimore"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep42503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42503","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T01:36:33Z","timestamp":1671845793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep42503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3,15]]}},"alternative-id":["BFsrep42503"],"URL":"https:\/\/doi.org\/10.1038\/srep42503","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,13]]},"assertion":[{"value":"1 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42503"}}